Investment in China’s pet care industry is rapidly expanding alongside its growing pet population – now the world’s third-largest, with over 62 million households owning companion animals. Chongqing-based biotechnology firm Hanpei Biology recently completed a funding round in the tens of millions of yuan, signaling increasing confidence in the nation’s ability to develop its own veterinary pharmaceutical solutions. The financing, led by Qinzhi Capital, will allow Hanpei Biology to accelerate the advancement and commercialization of novel drugs for the domestic pet market.
Chongqing-Based Hanpei Biology Secures Millions in Funding Round
Hanpei Biology, a Chongqing-based biotechnology firm, has completed a funding round raising tens of millions of yuan, according to multiple reports. The financing underscores growing investment in China’s domestic pet pharmaceutical sector.
The round was led by Qinzhi Capital, with participation from other investors, sources indicate. The company intends to use the funds to accelerate the development and commercialization of innovative veterinary drugs. This investment follows support from the Chongqing Municipal Seed Fund, which initially backed Hanpei Biology.
The Chongqing Seed Fund, designed to bolster early-stage companies, played a key role in facilitating Hanpei Biology’s access to capital. The fund’s support has been instrumental in helping the startup secure the recent multi-million yuan investment. The initiative demonstrates the Chongqing government’s commitment to fostering innovation within its local startup ecosystem.
Hanpei Biology is focused on developing novel pharmaceuticals for the pet market. The company’s progress highlights a broader trend of increasing investment in specialized animal healthcare solutions. The completion of this funding round is expected to expedite the launch of Hanpei Biology’s domestically produced pet medications.
Details of the specific amount raised were not disclosed, but reports consistently indicate a figure in the tens of millions of yuan. The company did not immediately respond to requests for comment. This funding round represents a significant milestone for Hanpei Biology as it aims to establish itself as a key player in the rapidly expanding Chinese pet pharmaceutical industry.
